Human cystatin C: A new biomarker of idiopathic pulmonary fibrosis?

Proteomics - Clinical Applications

Volumn 8, Issue 5-6, 2014, Pages 447-453

  Kasabova, Mariana ^a   Joulin Giet, Alix ^a   Lecaille, Fabien ^a   Saidi, Ahlame ^a   Marchand Adam, Sylvain ^a   Lalmanach, Gilles ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Cathepsin; Cystatin C; Lung fibrosis; Protease; Protease inhibitor

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; COLLAGENASE; CYSTATIN B; CYSTATIN C; CYSTATIN K; CYSTATIN L; CYSTATIN S; ENZYME PRECURSOR; PEPSTATIN; PEPTIDASE; PROTEINASE; SCLEROPROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CATHEPSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; HOMEOSTASIS; HUMAN; IMMUNOBLOTTING; IMMUNOCHEMISTRY; IMMUNOREACTIVITY; LUNG FUNCTION; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PROGNOSIS; ENZYMOLOGY; METABOLISM;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CATHEPSINS; CYSTATIN C; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE;

EID: 84902002938     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300047     Document Type: Article

References (42)

1. Bjoraker, J. A., Ryu, J. H., Edwin, M. K., Myers, J. L., Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 1998, 157, 199-203.
2. Naik, P. K., Moore, B. B., Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev. Respir. Med. 2010, 4, 759-771.
3. Raghu, G., Freudenberger, T. D., Yang, S., Curtis, J. R. et al., High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir. J. 2006, 27, 136-142.
4. King, T. E., Pardo, A., Selman, M., Idiopathic pulmonary fibrosis. Lancet 2011, 378, 1949-1961.
5. Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J. et al., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788-824.
6. Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U. et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377, 1760-1769.
7. Abrahamson, M., Alvarez-Fernandez, M., Nathanson, C-M., Cystatins. Biochem. Soc. Symp. 2003, 70, 179-199.
8. Turk, V., Bode, W., The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991, 285, 213-219.
9. Rawlings, N. D., Barrett, A. J., Bateman, A., MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012, 40, 343-350.
10. Wallin, H., Bjarnadottir, M., Vogel, L. K., Wassélius, J. et al., Cystatins-Extra- and intracellular cysteine protease inhibitors: high-level secretion and uptake of cystatin C in human neuroblastoma cells. Biochimie 2010, 92, 1625-1634.
11. Abrahamson, M., Barrett, A. J., Salvesen, G., Grubb, A., Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem. 1986, 261, 11282-11289.
12. Turk, V., Stoka, V., Turk, D., Cystatins: biochemical and structural properties, and medical relevance. Front. Biosci. J. 2008, 13, 5406-5420.
13. Lalmanach, G., Diot, E., Godat, E., Lecaille, F. et al., Cysteine cathepsins and caspases in silicosis. Biol. Chem. 2006, 387, 863-870.
14. Kasabova, M., Saidi, A., Naudin, C., Sage, J. et al., Cysteine cathepsins: markers and therapy targets in lung disorders. Clin. Rev. Bone Miner. Metab. 2011, 9, 148-161.
15. Odutayo, A., Cherney, D., Cystatin C and acute changes in glomerular filtration rate. Clin. Nephrol. 2012, 78, 64-75.
16. Grubb, A., Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check. Scand. J. Clin. Lab. Invest. 2010, 70, 65-70.
17. Bollengier, F., Cystatin C, alias post-gamma-globulin: a marker for multiple sclerosis? J. Clin. Chem. Clin. Biochem. 1987, 25, 589-593.
18. Takeuchi, M., Fukuda, Y., Nakano, I., Katano, Y. et al., Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur. J. Gastroenterol. Hepatol. 2001, 13, 951-955.
19. Chu, S.-C., Wang, C.-P., Chang, Y.-H., Hsieh, Y.-S. et al., Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin. Chim. Acta 2004, 341, 133-138.
20. Gressner, A. M., Lahme, B., Meurer, S. K., Gressner, O. et al., Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. World J. Gastroenterol. 2006, 12, 731-738.
21. Chung-Hung, T., Shun-Fa, Y., Yu-Chao, C., The upregulation of cystatin C in oral submucous fibrosis. Oral Oncol. 2007, 43, 680-685.
22. Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H. et al., A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012, 156, 684-691.
23. Naser, N., Clinical Chemistry Laboratory Manual, Mosby: St Louis, Missouri 1998.
24. Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T. et al., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461-470.
25. Quesnel, C., Marchand-Adam, S., Fabre, A., Marchal-Somme, J. et al., Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294, 334-343.
26. Serveau-Avesque, C., Martino, M. F.-D., Hervé-Grépinet, V., Hazouard, E. et al., Active cathepsins B, H, K, L and S in human inflammatory bronchoalveolar lavage fluids. Biol. Cell 2006, 98, 15-22.
27. Perdereau, C., Godat, E., Maurel, M.-C., Hazouard, E. et al., Cysteine cathepsins in human silicotic bronchoalveolar lavage fluids. Biochim. Biophys. Acta 2006, 1762, 351-356.
28. Naudin, C., Joulin-Giet, A., Couetdic, G., Plésiat, P. et al., Human cysteine cathepsins are not reliable markers of infection by Pseudomonas aeruginosa in cystic fibrosis. Plos One. 2011, 6, e25577.
29. Lecaille, F., Naudin, C., Sage, J., Joulin-Giet, A. et al., Specific cleavage of the lung surfactant protein A by human cathepsin S may impair its antibacterial properties. Int. J. Biochem. Cell Biol. 2013, 45, 1701-1709.
30. Chang, J. C., Lesser, M., Yoo, O. H., Orlowski, M., Increased cathepsin B-like activity in alveolar macrophages and bronchoalveolar lavage fluid from smokers. Am. Rev. Respir. Dis. 1986, 134, 538-541.
31. Ishii, Y., Hashizume, Y., Watanabe, T., Waguri, S. et al., Cysteine proteinases in bronchoalveolar epithelial cells and lavage fluid of rat lung. J. Histochem. Cytochem. 1991, 39, 461-468.
32. Lüthgens, K., Ebert, W., Trefz, G., Gabrijelcic, D. et al., Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients. Cancer Detect. Prev. 1993, 17, 387-397.
33. Reilly, J. J. Jr, Chen, P., Sailor, L. Z., Wilcox, D. et al., Cigarette smoking induces an elastolytic cysteine proteinase in macrophages distinct from cathepsin L. Am. J. Physiol. 1991, 261, 41-48.
34. Takahashi, H., Ishidoh, K., Muno, D., Ohwada, A. et al., Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. Am. Rev. Respir. Dis. 1993, 147, 1562-1568.
35. Schiffl, H., Lang, S. M., Update on biomarkers of acute kidney injury: moving closer to clinical impact? Mol. Diagn. Ther. 2012, 16, 199-207.
36. Lecaille, F., Kaleta, J., Brömme, D., Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 2002, 102, 4459-4488.
37. Reiser, J., Adair, B., Reinheckel, T., Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 2010, 120, 3421-3431.
38. Turk, V., Stoka, V., Vasiljeva, O., Renko, M. et al., Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824, 68-88.
39. Bühling, F., Röcken, C., Brasch, F., Hartig, R. et al., Pivotal role of cathepsin K in lung fibrosis. Am. J. Pathol. 2004, 164, 2203-2216.
40. Bühling, F., Waldburg, N., Reisenauer, A., Heimburg, A. et al., Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur. Respir. J. 2004, 23, 620-628.
41. Zhang, D., Leung, N., Weber, E., Saftig, P. et al., The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir. Res. 2011, 12, 72.
42. Zhang, D., Huang, C., Yang, C., Liu, R. J. et al., Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respir. Res. 2011, 12, 154.